Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial was written by von Tresckow, Julia;Cramer, Paula;Robrecht, Sandra;Langerbeins, Petra;Fink, Anna-Maria;Al-Sawaf, Othman;Fuerstenau, Moritz;Illmer, Thomas;Klaproth, Holger;Tausch, Eugen;Ritgen, Matthias;Fischer, Kirsten;Wendtner, Clemens-Martin;Kreuzer, Karl-Anton;Stilgenbauer, Stephan;Boettcher, Sebastian;Eichhorst, Barbara F.;Hallek, Michael. And the article was included in Leukemia in 2022.Recommanded Product: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid The following contents are mentioned in the article:
The prospective, open-label, multicenter phase II trial CLL2-BIG(registered atwww.clinicaltrials.govas # NCT02345863) was the first of the so called BXX trials of the German CLL Study Group (GCLLSG) [1] designed according to the “sequential triple-T” concept of a tailored and targeted treatment aiming attotal eradication of minimal residual disease(MRD). These trials aimed to evaluate novel combination therapies usingCD20-antibodies such as obinutuzumab (GA101) and targeted drugs such as ibrutinib with a limited duration of treatment in an all comer population irresp. of firstline (1 L) vs. relapse/refractory (RR) therapy, comorbidities and genetic features. Patients responding to IT continued with maintenance therapy (MT), consisting of daily ibrutinib and obinutuzumab every three months until achievement of an undetectable MRD (uMRD) remission by flow cytometry(10^-4), confirmed by two consecutive uMRD results in the peripheral blood (PB) within three months, progression, start of new therapy or for up to 24 mo, which everoccurred first. Here, we present the final anal. with extended follow-up including the maintenance phase and data on treatment discontinuation triggered by MRD assessment in PB. The median duration of response (DOR) was 38.0 mo and the 2-yr DOR rate 88.3% (1 L 100.0%, RR 77.4%). The median time to uMRD from the date of enrolment to the date of first uMRD was 10.9 mo (1 L 10.2 mo, RR 10.9 mo) as the first measurement took place after 8 mo. The median event free survival (EFS) was 44.8 mo with a 3-yr EFS rate of 70.9%(1 L 81.8%, RR 60.7%), the median treatment free survival and median time to next treatment were not reached with a 3-yearrate of 76.1% (1 L 89.0%, RR 64.0%) and 83.2% (1 L 89.0%, 77.2%),resp. Whether this is really playing a significant role in overcoming adverse outcomes, especially in patients with unmutated IGHV status orTP53aberrations, needs further evaluation. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Recommanded Product: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid).
4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3–C6) is higher than in water and generally decreases with a Imidazole derivatives have antibacterial, antifungal and anticancer functionality. It interacts with DNA and also binds to protein and stops cell division.Recommanded Product: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem